GE HealthCare Introduces Signa Sprint 1.5T MRI System at ISMRM Conference
The combination of high-performance gradient technology and AI tools with the Signa Sprint MRI reportedly facilitate enhanced MRI workflow efficiencies in cardiac and oncology imaging.
Emphasizing advances with qualitative magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI) and deep learning, GE HealthCare has unveiled the Signa™ Sprint 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025 conference in Honolulu, Hawaii.
Offering a high-gradient performance of 65/200 per axis, the Signa Sprint MRI platform provides enhanced visualization of sub-millimetric structures and facilitates a deeper understanding of tissue characteristics, according to GE HealthCare.
Offering a high-gradient performance of 65/200 per axis, the Signa Spirit 1.5T MRI platform combines deep learning reconstruction capabilities with enhanced diffusion-weighted imaging (DWI) for cardiac and oncology imaging applications. (Photo courtesy of GE HealthCare.)
Incorporating deep learning reconstruction capabilities, the company maintained that the Signa Sprint MRI system significantly reduces reading time for accelerated cardiac MRI scans.
“We are driven to push the boundaries of what’s possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response,” noted Kelly Londy, the CEO of MR at GE HealthCare. “We are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging.”
GE HealthCare noted that Signa Sprint is pending 510(k) clearance by the Food and Drug Administration (FDA).
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
